Global Biosimulation Market, By Product and Service (Software, Molecular Simulation, In House, Contract Services), Application (Drug Development, Drug Discovery, Other Applications), Delivery Model (Subscription Models, Ownership Models), End User (Biotech, Pharma Companies, Contract Research Organizations (CROs), Regulatory Authorities, Other End Users), – Industry Trends and Forecast to 2029
Biosimulation Market Analysis and Size
Developing a new drug requires a significant amount of research and resources. Every stage of the drug development process, from clinical trials to approval, has a very high failure rate. Bio simulation can significantly reduce these chances. Biosimulation not only helps predict the chances of a drug failing during the development process but also lowers the cost of any other possible failures by reducing the number of clinical experiments.
Data Bridge Market Research analyses that the biosimulation market was valued at USD 1.02 billion in 2021 and is expected to reach the value of USD 5.74 billion by the year 2029, at a CAGR of 24.1% during the forecast period. The rising number of drug relapses due to acquired drug resistance in diseases such as cancer, tuberculosis, and other bacterial infections will contribute to the biosimulation market's expansion. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Biosimulation is a mathematical simulation of a biological procedure that employs computer-aided programmes to simulate biological processes and systems. Model-based drug development refers to the ability to make data-driven decisions using a quantitative framework at all stages of drug development. Biosimulation is a promising technology that is used specifically in pharmaceutical research to improve the drug discovery and development cycle.
Biosimulation Market Scope and Segmentation
2022 to 2029
2020 (Customizable to 2014 - 2019)
Revenue in USD Billion, Volumes in Units, Pricing in USD
Product and Service (Software, Molecular Simulation, In House, Contract Services), Application (Drug Development, Drug Discovery, Other Applications), Delivery Model (Subscription Models, Ownership Models), End User (Biotech, Pharma Companies, Contract Research Organizations (CROs), Regulatory Authorities, Other End Users)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Certara (U.S.), Simulations Plus (U.S.), Dassault Systèmes (France), Schrödinger, Inc (U.S.), ACD/Labs (Canada), Chemical Computing Group (Canada), Physiomics (U.K.), Evidera (U.S.), In silico biosciences (U.S.), INOSIM Software (Germany), Insilico Biotechnology (Germany), LeadInvent Technologies (India), Rosa (U.S.), Nuventra Pharma (U.S.)
Biosimulation Market Dynamics
- The rise in the adoption of biosimulation software
The increase in R&D investments in the pharmaceutical and biotechnology industries, as well as the increased adoption of biosimulation software by regulatory bodies and technologically advanced QSP systems, are expected to drive the biosimulation market growth during the forecast period.
- The reduction in development costs and growth of biologics
The demands to reduce drug discovery and development costs, as well as the growth of the biologics and biosimilar markets, are expected to fuel the growth of the biosimulation market.
- Government investments for healthcare interoperability
The federal government's increased funding to drive the adoption of these solutions has further influenced the market. Furthermore, the increase in healthcare spending, advancements in healthcare infrastructure, and a high demand for expanded care delivery all benefit the biosimulation market.
The expanding applications and increased use of personalised medicine and biosimulation solutions for paediatric drug development will provide additional opportunities for the biosimulation market to grow in the coming years.
The lack of standardisation is also expected to stifle growth in the biosimulation market over the forecast period. The difficulty in matching the complexity of biological systems and processes and the scarcity of biosimulation and modelling experts may pose additional challenges to the biosimulation market's growth in the near future.
This biosimulation market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the biosimulation market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Covid-19 Impact on Biosimulation Market
The COVID-19 pandemic had a significant impact on the healthcare industry, including the biosimulation market. The need to test and develop COVID-19 vaccine candidates quickly fueled demand for biosimulation software and services.
Advanced Chemistry Development will release new updates for its Percepta and Spectrus platform applications in September 2020. This expanded the company's product offerings by including new features like NMR and M.S. functionality for data analysis and 3D optimization in the chromatography lineup.
Global Biosimulation Market Scope
The biosimulation market is segmented on the basis of product and service, application, delivery model and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product and Service
- Molecular simulation
- In house
- Contract services
On the basis of product and Service, the biosimulation market is segmented into software, molecular simulation, in house, contract services. Software is further sub segmented into lecular modeling and simulation software, PBPK modeling and simulation software, PK/PD modeling and simulation software, trial design software, toxicity prediction software and other biosimulation software. A contract service is further sub segmented into in-house services and contract services.
- Drug development
- Drug discovery
- Other application
On the basis of application, the biosimulation market is segmented into drug development, drug discovery, and other applications. Drug development is further sub segmented into preclinical testing and clinical trials. Preclinical testing is further sub segmented into PK/PD and ADME/TOX. Drug discovery is further sub segmented into target identification and validation and lead identification and optimization.
- Subscription model
- Ownership model
On the basis of delivery model, the biosimulation market is segmented into subscription models, ownership models.
- Healthcare Payers
- Regulatory authorities
- Contract research organizations
On the basis of end user, the biosimulation market is segmented into biotech, pharma companies, contract research organizations (CROs), regulatory authorities, other end users.
Biosimulation Market Regional Analysis/Insights
The biosimulation market is analysed and market size insights and trends are provided by country, product and service, application, delivery model and end user as referenced above.
The countries covered in the biosimulation market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Due to the general increasing number of collaborations between key players to improve drug discovery capabilities, North America dominates the biosimulation market. Furthermore, the use of in-silico models during regulatory policy enforcement to ensure high patient safety and treatment standards will drive the region's biosimulation market growth during the forecast period. The Asia Pacific biosimulation market is expected to grow significantly due to a growing preference for contract research organisations and rising healthcare I.T. expenditure. Furthermore, consistent improvements in healthcare infrastructure and increased research and development activities in developing countries are expected to drive the growth of the biosimulation market in the region in the coming years.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The biosimulation market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for biosimulation market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the biosimulation market. The data is available for historic period 2010-2020.
Competitive Landscape and Biosimulation Market Share Analysis
The biosimulation market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to biosimulation market.
Some of the major players operating in the biosimulation market are
- Certara (U.S.)
- Simulations Plus (U.S.)
- Dassault Systèmes (France)
- Schrödinger, Inc (U.S.)
- ACD/Labs (Canada)
- Chemical Computing Group (Canada)
- Physiomics (U.K.)
- Evidera (U.S.)
- In silico biosciences (U.S.)
- INOSIM Software (Germany)
- Insilico Biotechnology (Germany)
- LeadInvent Technologies (India)
- Rosa (U.S.)
- Nuventra Pharma (U.S.)